EUVIMEDEUVIMED entdecken
Crossref

Monocyte Membrane-Fused Liposomes for Enhanced Targeted Treatment of Mesangioproliferative Glomerulonephritis

Honglin Gao, Yujia Wang, Jiali Fu, Yan Yuan, Ting Li, Anqi Zhang, Weichang He, Shanshan He, Shiqi Huang, Lin Li, Mengke Qu, Ling Guo iD und 5 weitere

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c18857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Honglin Gao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Liposomes, Monocytes, Glomerulonephritis, Membranoproliferative. Die Arbeit nennt 60 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rising incidence of end-stage renal disease, with mesangioproliferative glomerulonephritis (MsPGN) as a major contributor, underscores the urgent need for safe and effective therapeutic strategies. In this study, we developed monocyte membrane-fused liposomes loaded with celastrol (M-Lipo@CLT) to exploit the innate inflammatory homing capacity of monocytes for precise glomerular targeting. The monocyte-derived membrane functioned both as a targeting component and as a reservoir enabling active inflammation-specific drug delivery, thereby enhancing selective drug accumulation at diseased glomeruli. M-Lipo@CLT were fabricated via thin-film hydration followed by membrane extrusion, yielding uniform spherical nanoparticles with an average diameter of 80.0 ± 5.3 nm, a polydispersity index of 0.155 ± 0.050, and a zeta potential of -11.89 ± 1.5 mV. In vitro, M-Lipo@CLT demonstrated markedly increased cellular uptake, particularly under inflammatory conditions, in both RAW264.7 macrophages and HBZY-1 mesangial cells, confirming their inflammation-targeting capability. In vivo, employing a rat Thy1.1 MsPGN model, M-Lipo@CLT achieved superior renal and glomerular accumulation compared with conventional liposomes, leading to significant inhibition of mesangial cell proliferation, attenuation of renal inflammation, and preservation of glomerular architecture. Furthermore, safety assessments revealed substantially reduced systemic toxicity relative to free celastrol, highlighting the improved biocompatibility and minimized off-target effects of the formulation. Collectively, these results established M-Lipo@CLT as a promising glomerulus-targeted nanomedicine with enhanced efficacy and improved safety, offering a potential strategy for the treatment of MsPGN and other inflammation-driven diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesMonocytesGlomerulonephritis, MembranoproliferativeAnimalsMicePentacyclic TriterpenesRatsRAW 264.7 CellsMaleTriterpenesHumansRats, Sprague-DawleyCell ProliferationDrug Delivery Systems

Stichwörter der Autor:innen

biomimetic liposomescelastrolglomerular targetingglomerulonephritismonocyte membranerenal nanomedicine

Substanzen

LiposomesPentacyclic TriterpenescelastrolTriterpenes

Autor:innen und Institutionen

  • Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
  • College of Polymer Science and Engineering, Sichuan University, Chengdu 610065, P. R. China.
  • West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, P. R. China.
  • Chengdu Daofei Technology Ltd., Chengdu 610041, P. R. China.
  • National Engineering Technology Research Center for Miao Medicine, Guizhou Engineering Technology Research Center for Processing and Preparation of Traditional Chinese Medicine and Ethnic Medicine, College of Pharmaceut…

ORCID-Profile: Ling Guo, Tao Gong, Ling Zhang, Qing Lin, Zhirong Zhang

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

Gao, H., Wang, Y., Fu, J., Yuan, Y., Li, T., Zhang, A., He, W., He, S., Huang, S., Li, L., Qu, M., Guo, L., Sun, X., Gong, T., Zhang, L., Lin, Q., & Zhang, Z. (2025). Monocyte Membrane-Fused Liposomes for Enhanced Targeted Treatment of Mesangioproliferative Glomerulonephritis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c18857

Vancouver

Gao H, Wang Y, Fu J, Yuan Y, Li T, Zhang A, et al. Monocyte Membrane-Fused Liposomes for Enhanced Targeted Treatment of Mesangioproliferative Glomerulonephritis. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c18857

BibTeX
@article{Gao2025,
  author = {Gao, Honglin and Wang, Yujia and Fu, Jiali and Yuan, Yan and Li, Ting and Zhang, Anqi and He, Weichang and He, Shanshan and Huang, Shiqi and Li, Lin and Qu, Mengke and Guo, Ling and Sun, Xun and Gong, Tao and Zhang, Ling and Lin, Qing and Zhang, Zhirong},
  title = {Monocyte Membrane-Fused Liposomes for Enhanced Targeted Treatment of Mesangioproliferative Glomerulonephritis},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c18857}
}
Kostenlos starten →